<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11973">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00528931</url>
  </required_header>
  <id_info>
    <org_study_id>AUX-CC-855</org_study_id>
    <nct_id>NCT00528931</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study of AA4500 (XIAFLEX™, Proposed Name) in Subjects With Dupuytren's Contracture</brief_title>
  <official_title>A Phase 1, Open-Label Study to Assess the Pharmacokinetics and Safety of a Single Injection of AA4500 0.58 mg in Subjects With Dupuytren's Contracture</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endo Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, open-label, single-dose pharmacokinetic study in subjects with Dupuytren's
      contracture conducted at one site in the United States. All subjects received a single dose
      of AA4500 0.58 mg, which was injected directly into the cord affecting either the
      metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint. Pharmacokinetic blood
      samples were collected before dosing, at predetermined time points through the 24 hours
      after dosing, Day 7, and Day 30. Efficacy and safety assessments were performed up to 30
      days after the AA4500 0.58 injection.

      This study was designed to be part of the larger clinical program, for adult patients with
      Dupuytren's contracture with a palpable cord, where the data from 2 pivotal
      Placebo-Controlled studies (AUX-CC-857 [NCT00528606]and AUX-CC-859 [NCT00533273]) and 7
      non-pivotal studies were evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Number of Subjects With AUX I and AUX II Detected in Their Blood After a Single Dose of AA4500</measure>
    <time_frame>Before dosing, at predetermined time points through the 24 hours after dosing, Day 7, and Day 30</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>30 days after treatment to the primary joint</time_frame>
    <safety_issue>No</safety_issue>
    <description>A clinical success is defined as a reduction in contracture (ie, flexion deformity) to ≤ 5° of normal as measured by finger goniometry 30 days after an injection. If the Day 30 visit is missing, the last observation carried forward (LOCF) completed after the injection (Day 1 or Day 7) will be used to determine clinical success</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Improvement</measure>
    <time_frame>30 days after first treatment to the primary joint</time_frame>
    <safety_issue>No</safety_issue>
    <description>A clinical improvement is defined as a ≥ 50% reduction from baseline in contracture after an injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Reduction From Baseline Contracture</measure>
    <time_frame>30 days after first treatment to the primary joint</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Range of Motion</measure>
    <time_frame>30 days after first treatment to the primary joint</time_frame>
    <safety_issue>No</safety_issue>
    <description>Difference between the finger extension angle and finger flexion angle expressed in degrees</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Achieve and Maintain Clinical Success</measure>
    <time_frame>First evaluation visit on which clinical success is achieved and maintained through the Day 30 evaluation of the primary joint</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to clinical success is defined as the number of days after the first injection in the joint to reach clinical success</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Dupuytren's Contracture</condition>
  <arm_group>
    <arm_group_label>AA4500 0.58 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>collagenase clostridium histolyticum</intervention_name>
    <description>Single dose of AA4500 0.58 mg into the cord</description>
    <arm_group_label>AA4500 0.58 mg</arm_group_label>
    <other_name>XIAFLEX®</other_name>
    <other_name>AA4500</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a diagnosis of Dupuytren's contracture, with a fixed flexion deformity
             of at least one finger, other than the thumb, that had a contracture at least 20°,
             but not greater than 100° for MP (80° for PIP) joints, caused by a palpable cord.

          -  Had a positive &quot;table top test,&quot; defined as the inability to simultaneously place the
             affected finger(s) and palm flat against a table top.

          -  Were naive to AA4500 treatment.

          -  Were judged to be in good health.

        Exclusion Criteria:

          -  Had a chronic muscular, neurological, or neuromuscular disorder that affected the
             hands.

          -  Had received treatment for Dupuytren's contracture within 90 days of the AA4500
             injection to the MP or PIP selected, including surgery (fasciectomy or surgical
             fasciotomy), needle aponeurotomy/fasciotomy, or injection of verapamil and/or
             interferon on the selected primary joint within 90 days before the first dose of
             study drug.

          -  Had a known recent history of stroke, bleeding, a disease process that affected the
             hands, or other medical condition, which in the investigator's opinion, would make
             the subject unsuitable for enrollment in the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veronica Urdaneta, MD</last_name>
    <role>Study Director</role>
    <affiliation>Endo Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Providence Clinical Research</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/downloads/Drugs/DrugSafety/UCM200615.pdf</url>
    <description>XIAFLEX Medication Guide</description>
  </link>
  <link>
    <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125338lbl.pdf</url>
    <description>XIAFLEX Prescribing Information</description>
  </link>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 12, 2015</lastchanged_date>
  <firstreceived_date>September 11, 2007</firstreceived_date>
  <firstreceived_results_date>September 24, 2010</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Assessment of AUX I and/or AUX II in human plasma</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Contracture</mesh_term>
    <mesh_term>Dupuytren Contracture</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AA4500 0.58 mg</title>
          <description>collagenase clostridium histolyticum 0.58mg injected into either the metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AA4500 0.58 mg</title>
          <description>collagenase clostridium histolyticum 0.58mg injected into either the metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="60.6" spread="11.74"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With AUX I and AUX II Detected in Their Blood After a Single Dose of AA4500</title>
        <time_frame>Before dosing, at predetermined time points through the 24 hours after dosing, Day 7, and Day 30</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>collagenase clostridium histolyticum 0.58mg injected into either the metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With AUX I and AUX II Detected in Their Blood After a Single Dose of AA4500</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success</title>
        <description>A clinical success is defined as a reduction in contracture (ie, flexion deformity) to ≤ 5° of normal as measured by finger goniometry 30 days after an injection. If the Day 30 visit is missing, the last observation carried forward (LOCF) completed after the injection (Day 1 or Day 7) will be used to determine clinical success</description>
        <time_frame>30 days after treatment to the primary joint</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Improvement</title>
        <description>A clinical improvement is defined as a ≥ 50% reduction from baseline in contracture after an injection</description>
        <time_frame>30 days after first treatment to the primary joint</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Reduction From Baseline Contracture</title>
        <time_frame>30 days after first treatment to the primary joint</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Range of Motion</title>
        <description>Difference between the finger extension angle and finger flexion angle expressed in degrees</description>
        <time_frame>30 days after first treatment to the primary joint</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Achieve and Maintain Clinical Success</title>
        <description>Time to clinical success is defined as the number of days after the first injection in the joint to reach clinical success</description>
        <time_frame>First evaluation visit on which clinical success is achieved and maintained through the Day 30 evaluation of the primary joint</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time that the first dose of study drug was administered until 30 days elapsed following discontinuation of study drug administration.</time_frame>
      <desc>This study was designed to be part of the larger clinical program. For information regarding XIAFLEX-associated Serious and Non-serious Adverse events please refer to the XIAFLEX Medication Guide &amp; XIAFLEX Prescribing Information (see links above).</desc>
      <group_list>
        <group group_id="E1">
          <title>AA4500 0.58 mg</title>
          <description>collagenase clostridium histolyticum 0.58mg injected into either the metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.0</frequency_threshold>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Injection site oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Auxilium Pharmaceuticals, Inc. agreements may vary with individual investigators but will not prohibit any investigator from publishing. Auxilium supports the publication of results from all centers of a multicenter trial but requests that reports based on single site data not preceed the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Veronica Urdaneta, MD</name_or_title>
      <organization>Endo Pharmaceuticals</organization>
      <phone>484-216-7721</phone>
      <email>urdaneta.veronica@endo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
